No Data
No Data
Otonomy (NASDAQ:OTIC) Research Coverage Started at StockNews.com
Research analysts at StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report issued to clients and investors on Monday. The firm set a "hold" rating on the
Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com
StockNews.com began coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company's stock.
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics acquires assets from Otonomy, including data, patent rights, and inventory related to OTO-104, OTO-510, and OTO-413 Clinical data analysis suggests Spiral's lead candidate, SPT-21
Olema Pharmaceuticals (NASDAQ:OLMA) and Otonomy (NASDAQ:OTIC) Critical Comparison
Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) and Otonomy (NASDAQ:OTIC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based
Requisite Capital Management LLC Acquires Shares of 150,000 Otonomy, Inc. (NASDAQ:OTIC)
Requisite Capital Management LLC acquired a new stake in Otonomy, Inc. (NASDAQ:OTIC – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Ex
StockNews.com Initiates Coverage on Otonomy (NASDAQ:OTIC)
StockNews.com began coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company'
No Data